We focused on the hypoglycemic effects of antidiabetic, glimepiride, and the antilipidemic, bezafibrate, in combination, and conducted basic investigations of their pharmacokinetics (PK) and effects using rats. Compared to the PK characteristics of glimepiride, bezafibrate indicated prolonged retention in the body at monotherapy. When both drugs were co-administered, the tissue distribution of bezafibrate increased, although the PK of glimepiride was almost unchanged. Bezafibrate at monotherapy exhibited a similar degree of hypoglycemic effect to the control group. In the case of co-administration, the hypoglycemic effect was almost the same and was sustained compared to monotherapy with glimepiride. This possibly reflects the effect of bezafibrate. The hypoglycemic effect at co-administration was approximated using mathematical model assuming that the effect calculated was additive, and the results matched the measured values.
Kiriyama et al. (Wed,) studied this question.